ATC Group: N06AX22 Agomelatine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06AX22 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06A Antidepressants
4 N06AX Other antidepressants
5 N06AX22 Agomelatine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 25 mg

Active ingredients in N06AX22

Active Ingredient Description
Agomelatine

Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.

Related product monographs

Title Information Source Document Type  
AGOMAVAL Film-coated tablet Medicines Authority (MT) MPI, EU: SmPC
THYMANAX Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
VALDOXAN Film-coated tablets European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Brazil (BR)

Cyprus (CY)

Ecuador (EC)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Malta (MT)

Netherlands (NL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.